Karen S. Gustafson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Karen S. Gustafson has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Brigitte M. Ronnett
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland
1 shared publicationDaniel F. Heitjan
Department of Biostatistics and Epidemiology, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania
1 shared publicationDouglas P. Clark
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland
1 shared publicationEmma E. Furth
Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania
1 shared publication- Leonard Feldman
Department of Medicine Johns Hopkins University School of Medicine Baltimore Maryland USA
1 shared publication Patti E. Gravitt
Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland
1 shared publication
Latest Publications
- 31 January 2008
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 10 (1) , 33-42
Locked Nucleic Acids Can Enhance the Analytical Performance of Quantitative Methylation-Specific Polymerase Chain Reaction
- 31 January 2008
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 10 (1) , 33-42
Locked Nucleic Acids Can Enhance the Analytical Performance of Quantitative Methylation-Specific Polymerase Chain Reaction
- Open Access
Quantitative methylation-specific PCR for the detection of aberrant DNA methylation in liquid-based Pap tests
BACKGROUND. Aberrant promoter methylation of selective tumor suppressor genes has been detected in squamous intraepithelial lesions (SIL) and invasive cervical cancer. Identification of methylation profiles of genes that can distinguish high‐grade SIL (HSIL) from low‐grade SIL (LSIL), and cytologically negative for intraepithelial lesion or malignancy (NILM) residual liquid‐based Papanicolaou (Pap) tests may be potentially useful as an ancillary test for cervical cancer screening. METHODS. Using real‐time quantitative methylation‐specific polymerase chain reaction (PCR) (QMSP), the authors analyzed the frequency and relative level of promoter methylation for DAPK1, IGSF4, SPARC, and TFPI2 in biopsy‐confirmed HSIL and LSIL, and NILM residual liquid‐based Pap tests. The percentage of methylation (%M) for each gene was calculated using the reference gene, ACTB. The cumulative methylation score for each sample, defined as the sum of %M of all 4 genes, was used to analyze the genes in combination. RESULTS. For each gene analyzed the frequency and relative level of methylation were increased in HSIL compared with combined NILM/LSIL samples. The cumulative methylation scores were significantly higher in HSIL samples (P < .0001). Area under the receiver operating characteristic (ROC) curve (AUC) demonstrated that methylation of each gene could distinguish HSIL from NILM/LSIL samples (AUC range, 0.6–0.67; P ≤ .0028). The combination of 4 genes showed improved test performance (AUC = 0.76; P < .0001). There was no significant difference in cumulative methylation in HSIL cases with histologic outcomes of cervical intraepithelial neoplasia grade 2 (CIN2) versus CIN3. There was no association between the methylation of any gene and the presence of human papillomavirus. CONCLUSIONS. The methylation profile of multiple genes in combination can better distinguish HSIL from combined NILM/LSIL samples. Although aberrant DNA methylation has the potential to function as a molecular biomarker of HSIL in liquid‐based Pap tests, additional genes that are selectively methylated in HSIL are needed to improve the clinical performance. Cancer (Cancer Cytopathol) 2008. © 2008 American Cancer Society.
Open AccessQuantitative methylation-specific PCR for the detection of aberrant DNA methylation in liquid-based Pap tests
BACKGROUND. Aberrant promoter methylation of selective tumor suppressor genes has been detected in squamous intraepithelial lesions (SIL) and invasive cervical cancer. Identification of methylation profiles of genes that can distinguish high‐grade SIL (HSIL) from low‐grade SIL (LSIL), and cytologically negative for intraepithelial lesion or malignancy (NILM) residual liquid‐based Papanicolaou (Pap) tests may be potentially useful as an ancillary test for cervical cancer screening. METHODS. Using real‐time quantitative methylation‐specific polymerase chain reaction (PCR) (QMSP), the authors analyzed the frequency and relative level of promoter methylation for DAPK1, IGSF4, SPARC, and TFPI2 in biopsy‐confirmed HSIL and LSIL, and NILM residual liquid‐based Pap tests. The percentage of methylation (%M) for each gene was calculated using the reference gene, ACTB. The cumulative methylation score for each sample, defined as the sum of %M of all 4 genes, was used to analyze the genes in combination. RESULTS. For each gene analyzed the frequency and relative level of methylation were increased in HSIL compared with combined NILM/LSIL samples. The cumulative methylation scores were significantly higher in HSIL samples (P < .0001). Area under the receiver operating characteristic (ROC) curve (AUC) demonstrated that methylation of each gene could distinguish HSIL from NILM/LSIL samples (AUC range, 0.6–0.67; P ≤ .0028). The combination of 4 genes showed improved test performance (AUC = 0.76; P < .0001). There was no significant difference in cumulative methylation in HSIL cases with histologic outcomes of cervical intraepithelial neoplasia grade 2 (CIN2) versus CIN3. There was no association between the methylation of any gene and the presence of human papillomavirus. CONCLUSIONS. The methylation profile of multiple genes in combination can better distinguish HSIL from combined NILM/LSIL samples. Although aberrant DNA methylation has the potential to function as a molecular biomarker of HSIL in liquid‐based Pap tests, additional genes that are selectively methylated in HSIL are needed to improve the clinical performance. Cancer (Cancer Cytopathol) 2008. © 2008 American Cancer Society.
- 17 January 2007
- Published by Wiley in Diagnostic Cytopathology
- Vol. 35 (2) , 103-104
Cryptococcal lymphadenitis diagnosed by fine‐needle aspiration biopsy
- 17 January 2007
- Published by Wiley in Diagnostic Cytopathology
- Vol. 35 (2) , 103-104
Cryptococcal lymphadenitis diagnosed by fine‐needle aspiration biopsy
DNA methylation profiling of cervical squamous intraepithelial lesions using liquid-based cytology specimens
BACKGROUND Cervical carcinoma is a common malignancy among women worldwide, and its pathogenesis is related causally to human papillomavirus infection. The progression from precursor squamous intraepithelial lesions to cervical carcinoma requires additional genetic and epigenetic alterations that have not been characterized fully. The authors examined aberrant promoter methylation of multiple tumor suppressor genes in precursor squamous intraepithelial lesions. METHODS A multiplex, nested, methylation‐specific polymerase chain reaction approach was used to examine promoter methylation of 15 tumor suppressor genes in high‐grade squamous intraepithelial lesions (HSIL, n = 11), low‐grade squamous intraepithelial lesions (LSIL, n = 17), and negative tissues (n = 11) from liquid‐based cytology samples. The area under the receiver‐operating characteristic (ROC) curve was determined for individual methylated tumor suppressor genes and for gene combinations to evaluate test performance for the ability of methylation profiles to distinguish HSIL cytology samples from combined LSIL/negative cytology samples. RESULTS Aberrant promoter methylation of DAPK1 and IGSF4 occurred at a high frequency in HSIL samples and was absent in LSIL and negative samples. There was a significant trend toward increased methylation with the increased severity of lesions, and the mean number of methylated genes was significantly higher in HSIL samples compared with LSIL and negative samples. Using the area under the ROC curve as a measure of test performance, the methylation of IGSF4 and DAPK1 had areas that were significantly greater than 0.5; thus, each had the ability to distinguish HSIL samples from combined LSIL/negative samples. The areas under the curve for the best two‐gene combination (IGSF4/DAPK1) and the best three‐gene combination (IGSF4/DAPK1/HIC1) were not statistically different from the best individual tumor suppressor gene (IGSF4) in distinguishing HSIL samples from combined LSIL/negative samples. CONCLUSIONS Aberrant promoter methylation of tumor suppressor genes is an epigenetic alteration that occurs during neoplastic progression to cervical carcinoma. The methylation status of multiple tumor suppressor genes can be evaluated using ROC analysis to determine methylation profiles that can distinguish HSIL samples from combined LSIL/negative samples. Cancer (Cancer Cytopathol) 2004. © 2004 American Cancer Society.
DNA methylation profiling of cervical squamous intraepithelial lesions using liquid-based cytology specimens
BACKGROUND Cervical carcinoma is a common malignancy among women worldwide, and its pathogenesis is related causally to human papillomavirus infection. The progression from precursor squamous intraepithelial lesions to cervical carcinoma requires additional genetic and epigenetic alterations that have not been characterized fully. The authors examined aberrant promoter methylation of multiple tumor suppressor genes in precursor squamous intraepithelial lesions. METHODS A multiplex, nested, methylation‐specific polymerase chain reaction approach was used to examine promoter methylation of 15 tumor suppressor genes in high‐grade squamous intraepithelial lesions (HSIL, n = 11), low‐grade squamous intraepithelial lesions (LSIL, n = 17), and negative tissues (n = 11) from liquid‐based cytology samples. The area under the receiver‐operating characteristic (ROC) curve was determined for individual methylated tumor suppressor genes and for gene combinations to evaluate test performance for the ability of methylation profiles to distinguish HSIL cytology samples from combined LSIL/negative cytology samples. RESULTS Aberrant promoter methylation of DAPK1 and IGSF4 occurred at a high frequency in HSIL samples and was absent in LSIL and negative samples. There was a significant trend toward increased methylation with the increased severity of lesions, and the mean number of methylated genes was significantly higher in HSIL samples compared with LSIL and negative samples. Using the area under the ROC curve as a measure of test performance, the methylation of IGSF4 and DAPK1 had areas that were significantly greater than 0.5; thus, each had the ability to distinguish HSIL samples from combined LSIL/negative samples. The areas under the curve for the best two‐gene combination (IGSF4/DAPK1) and the best three‐gene combination (IGSF4/DAPK1/HIC1) were not statistically different from the best individual tumor suppressor gene (IGSF4) in distinguishing HSIL samples from combined LSIL/negative samples. CONCLUSIONS Aberrant promoter methylation of tumor suppressor genes is an epigenetic alteration that occurs during neoplastic progression to cervical carcinoma. The methylation status of multiple tumor suppressor genes can be evaluated using ROC analysis to determine methylation profiles that can distinguish HSIL samples from combined LSIL/negative samples. Cancer (Cancer Cytopathol) 2004. © 2004 American Cancer Society.